ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

MiNA Therapeutics to present at Jefferies 2021 London Healthcare Conference

November 12, 2021 GMT

LONDON--(BUSINESS WIRE)--Nov 12, 2021--

MiNA Therapeutics Limited (“MiNA” or the “Company”), the pioneer in small activating RNA (saRNA) therapeutics, announces that its Chief Executive Officer, Robert Habib, will present and host one-on-one meetings at the Jefferies 2021 London Healthcare Conference, taking place from 16-19 November 2021 in-person and virtually.

MiNA’s presentation will take place at 3:40pm GMT on Tuesday, 16 November 2021, with a live webcast available via the following link: https://wsw.com/webcast/jeff201/mina/1827270.

ADVERTISEMENT

Mr Habib will introduce MiNA and its saRNA technology platform, as well as provide an update on the Company’s clinical progress and strategy.

About MiNA Therapeutics

MiNA Therapeutics is the leader in small activating RNA therapeutics. Harnessing innate mechanisms of gene activation, small activating RNA therapeutics are a revolutionary new class of medicines that can restore or boost normal function in patients’ cells. We are advancing a proprietary pipeline of new medicines with an initial focus on cancer and genetic diseases, while collaborating with leading pharmaceutical companies to apply our technology platform across a broad range of therapeutic areas. Based on our unique know-how in RNA activation we are expanding the possibilities of RNA-based medicine for patients. www.minatx.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20211112005192/en/

CONTACT: Contact:

MiNA Therapeutics

Robert Habib, CEO / Robin Wright, CFO

Phone: +44 208 811 6700

E-Mail:info@minatx.com

Media requests:

ADVERTISEMENT

Victoria Foster Mitchell / Tim Stamper

FTI Consulting

Phone: +44 203 727 1000

E-Mail:MiNATherapeutics@fticonsulting.com

KEYWORD: UNITED KINGDOM EUROPE

INDUSTRY KEYWORD: ONCOLOGY HEALTH GENETICS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: MiNA Therapeutics Limited

Copyright Business Wire 2021.

PUB: 11/12/2021 07:00 AM/DISC: 11/12/2021 07:01 AM

http://www.businesswire.com/news/home/20211112005192/en